ArticleBMC musculoskeletal disorders2026
Remnant-preserving selective posterolateral bundle reconstruction for partial ACL tears: a retrospective comparative study of functional outcomes, graft maturation, and return-to-sport rates with and without biologic augmentation.
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare functional outcomes, MRI graft maturation, and return-to-sport rates following remnant-preserving selective posterolateral (PL) bundle anterior cruciate ligament (ACL) reconstruction with and without intraoperative leukocyte-poor platelet-rich plasma (PRP) augmentation in patients with arthroscopically confirmed isolated PL-bundle tears.
methodsThis retrospective comparative cohort study included all consecutive patients who underwent standardized remnant-preserving selective PL-bundle ACL reconstruction using quadrupled semitendinosus autograft at a single institution between January 2020 and December 2023. Patients were allocated to two parallel groups according to an institutional protocol change in July 2022: no biologic augmentation (Group A) or leukocyte-poor PRP injected at the graft–remnant interface and tibial tunnel (Group B). All procedures were performed by the same senior surgeon with an identical anatomic transportal technique, and all patients followed the same accelerated, criterion-based rehabilitation protocol.
resultsReturn to pre-injury sport level at 24 months was achieved by 69% in Group A versus 88% in Group B (risk ratio 1.28, 95% CI 1.01–1.63; p = 0.029), with mean return time 9.3 ± 1.7 versus 7.4 ± 1.4 months (p = 0.002). The advantage persisted after multivariable adjustment (adjusted OR 3.1, 95% CI 1.2–8.4; p = 0.022). Knee stability (KT-1000 1.4 ± 0.8 vs. 1.2 ± 0.7 mm; p = 0.19) and IKDC scores (95.4 ± 3.2 vs. 96.2 ± 2.9; p = 0.11) were equivalent. At 12 months, the PRP group showed superior graft maturation (signal-to-noise quotient 2.7 ± 0.9 vs. 1.8 ± 0.6, p < 0.001; mature ligamentization 64% vs. 86%, p = 0.008; tunnel widening 1.9 ± 0.7 vs. 1.4 ± 0.5 mm, p = 0.002), better neuromuscular symmetry, proprioception, and ACL-RSI scores. Complications were low and comparable (9.5% vs. 7.0%; p = 0.66), with no graft failures.
conclusionLeukocyte-poor PRP augmentation significantly enhanced return-to-sport rates and timelines, early graft maturation, and neuromuscular recovery after remnant-preserving selective PL-bundle ACL reconstruction while preserving equivalent long-term stability and safety. Prospective randomized trials are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.